Video

Early Treatment for Myelodysplastic Syndrome: Many Patients Are Missing Out

Author(s):

Christopher Cogle, M.D.

Many patients with myelodysplastic syndrome are not receiving early treatment.

About two-thirds of patients with myelodysplastic syndrome (MDS) are not being given early treatment, according to Christopher Cogle, M.D., a professor of Medicine at the University of Florida Health.

Cogle was involved with a study that examined which patients were more likely to be treated with Vidaza (azacitidine), Dacogen (decitabine) or Revlimid (lenalidomide). While he initially thought that age and frailness would be the factors that were associated with not being treated, he actually found that it was patients with higher-risk disease, private insurance and genetic testing who were more likely to be prescribed one of the three agents.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Related Content
Jane Biehl is a 12-year survivor of a very rare form of blood cancer, known as myelodysplastic syndrome (MDS). Catch up on all of Jane’s blogs here!
April 24th 2025

Taking Charge of My Care and Advocacy Following a Cancer Diagnosis

Jane Biehl Ph.D.
After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.
Illustration of blood cell.
April 16th 2025

Bexmarilimab Plus Vidaza Elicit Responses in Myelodysplastic Syndromes

Ryan Scott
Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome.
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
Illustration of woman.
April 8th 2025

Sometimes Cancer is a (Welcome) Distraction

Jane Biehl Ph.D.
In an upside-down, topsy-turvy world, cancer can be a distraction for us.
image of dr. Lillian Siu.
April 3rd 2025

Breaking Down Early Signs and Symptoms of Head and Neck Cancer

Dr Lillian Siu
April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.
The EC has approved Rytelo in transfusion-dependent anemia due to very low–, low– or intermediate-risk myelodysplastic syndrome: © Crystal_Light - stock.adobe.com.
March 25th 2025

EU Approves Rytelo for Transfusion-Dependent Anemia in Low-Risk MDS

Ryan Scott
The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or intermediate-risk myelodysplastic syndrome.